VATS Lobectomy for Lung Cancer

Taking less lung left twice as much cancer behind in the chest. Five year survival came out better anyway.

JCOG0802 randomized 1,106 patients with clinical stage IA tumors of two centimeters or less between removing the whole lobe and removing one segment of it. Local relapse ran at 10.5 percent after segmentectomy and 5.4 percent after lobectomy. Five-year overall survival was 94.3 percent and 91.1 percent, favoring the smaller operation, and the trial met its threshold for superiority.

One phrase, two separate decisions

VATS lobectomy names two choices at once. Patients rarely get told they are separate. How the surgeon gets into the chest is one decision, and how much lung comes out is the other.

Conflating the two sends patients into the wrong argument. Reading that keyhole surgery is better teaches you nothing at all about whether you need a lobe removed or a segment of one, and being told you need a lobectomy teaches you nothing about how it will be done. They are different conversations with different evidence behind them.

Why the distinction matters at the consultation

Everything below separates them and then puts them back together.

The access question, and why it is settled

Keyhole lung surgery spread across the world for two decades on the strength of observational data, which is a weaker foundation than it sounds. Two randomized trials eventually tested it properly.

Drag the table sideways on a narrow screen.

What the two trials measured, and what they did not

The oncological result did not change and everything else did. That is what settled the question, and it is also why a surgeon offering an open operation now needs a specific reason for it.

Such reasons exist. A tumor invading the chest wall, a central tumor sitting on the pulmonary artery, dense scarring from previous infection or previous surgery, and the need for a sleeve resection all push toward opening the chest. None of those is a failure of technique. A surgeon who never opens a chest is patients instead of treating them.

How much lung comes out, and the finding that surprised the field

Lobectomy has been the standard operation for lung cancer since a trial in the 1990s found that smaller resections recurred more. That trial was small, it predated modern imaging, and it settled the question for thirty years. Two trials reopened it.

Two randomized trials reopened a question that a single small study had closed thirty years earlier, and they reopened it in the direction nobody expected.

The Japanese trial, which found superiority

JCOG0802 enrolled 1,106 patients at 70 institutions in Japan, all with clinical stage IA disease, tumors of two centimeters or less, and a consolidation-to-tumor ratio above 0.5 on thin-section CT, which is a way of saying the tumor was solid and not hazy. Randomization sent half to lobectomy and half to segmentectomy. At a median follow-up of 7.3 years, five-year overall survival came out at 94.3 percent after segmentectomy and 91.1 percent after lobectomy, with a hazard ratio of 0.663 that met the threshold for superiority and not merely for non-inferiority. Relapse-free survival landed at 88 percent in both arms. And local relapse ran at twice the rate after the smaller operation, 10.5 percent against 5.4 percent, and that difference reached statistical significance on its own, rather than appearing as noise. Three findings from a single trial, pulling in three different directions, and only one arrangement fits all three of them at once.

Those three findings only fit together one way. Segmentectomy left more disease behind in the chest and the patients still lived longer, because more of the lobectomy patients died of something other than lung cancer.

That was reported directly and not inferred. Of the deaths after lobectomy, 63 percent came from other diseases. After segmentectomy, 47 percent. Lung function at one year differed by 3.5 percent of predicted FEV1 in favor of segmentectomy, which the investigators had prespecified as below the level they would call clinically meaningful, so the mechanism is not simply that patients could breathe better afterwards. What the numbers describe is a population in which a smaller operation left people better able to survive the next twenty years of everything else that kills people in their seventies. Nobody predicted that shape of result, and it explains why this trial changed practice while its American counterpart merely confirmed safety. Competing mortality is an unglamorous phrase for the most consequential finding in early-stage lung surgery this decade, and it means something concrete for a patient sitting in a clinic. The lung you keep is doing work for the twenty years after the cancer is gone.

The American trial, which found non-inferiority

CALGB 140503 randomized 697 patients with tumors of two centimeters or less, after confirming during the operation that the hilar and mediastinal nodes were clear. Sublobar resection came out non-inferior to lobar resection for disease-free survival at a hazard ratio of 1.01, with five-year disease-free survival of 63.6 percent against 64.1 percent and five-year overall survival of 80.3 percent against 78.9 percent. Predicted FEV1 at six months favored the smaller operation by two percentage points. Recurrence patterns did not differ substantially. No signal pointed the other way.

Two trials, two designs, two different populations, and the same direction of travel. For a small solid tumor with clear nodes, the lobe is no longer automatically the answer.

Which operation fits which tumor

What pushes the decision one way or the other

Scroll the table sideways if your screen is narrow.

Look again at that last row, which connects to a separate decision. For a small peripheral tumor in someone who cannot have an operation at all, stereotactic radiotherapy is a genuine alternative with its own randomized evidence, and it belongs in the conversation before a borderline patient is pushed toward surgery they may not tolerate.

The lymph nodes, where a keyhole operation can quietly fall short

Removing the tumor is one job. The lymph node dissection is what tells you what stage the disease really is, and staging decides whether you need chemotherapy afterwards.

The theoretical risk, and what the trial found

Here the small-incision approach carries a real theoretical risk, because reaching the nodal stations through keyhole ports is harder than reaching them through an open chest. The VIOLET trial addressed it directly and found that upstaging from clinically node-negative to pathologically node-positive disease happened at the same rate in both arms, which is the measurement that matters, because a keyhole operation that missed positive nodes would show fewer of them. That reassurance is specific to an adequate dissection performed by a surgeon who does this regularly, and it is not a property of the instruments. The nodal stations do not become easier to reach because the incisions are small, so what the trial demonstrated is that experienced surgeons clear them just as well through ports, which is a different claim from saying the approach makes no difference to anyone who attempts it.

Get the node count. It ranks as the single most informative number in the whole operation report, and almost nobody requests it.

Robotic or thoracoscopic

Patients ask this constantly. What the evidence supports is narrower than the marketing.

A single-center randomized trial enrolled 320 patients between robotic-assisted and video-assisted lobectomy. Length of stay matched. So did complication rates. Neither arm had a perioperative death. Chest tube drainage ran higher in the robotic group. Hospitalization cost was substantially higher in the robotic group, by more than half again. The robotic group did harvest more lymph nodes, at a median of 11 against 10, more N1 nodes, and more nodal stations examined, and all three of those differences reached statistical significance.

How to read that

One extra lymph node at the median is a real difference and a small one, and whether it translates into better long-term outcomes is exactly what the trial could not answer, since it reported short-term results only. Both approaches use keyhole access and both avoid spreading the ribs, which is where the large benefit over open surgery comes from, so choosing between them on the platform means choosing on the weakest available evidence in the field. Choose instead on which operation your surgeon performs most weeks of the year. That is the strongest evidence available to any individual patient, it is easy to ask about, and it has the awkward property of being a question no brochure answers. Volume is not a proxy for skill and it is the best proxy available to a patient, which is an uncomfortable thing to write and a useful thing to know before choosing where to have a lobe removed.

One extra lymph node at the median, at substantially higher cost, with no measured difference in length of stay or in complications. That is the whole of the randomized evidence on this question.

Find out how many of your operation the surgeon performs in a year. That answer predicts your result better than the equipment does.

Whether you are fit for it

Lung cancer and poor lung function share a cause, so a large share of patients who need this operation are the patients least able to lose lung.

1. Lung function testing. Spirometry for FEV1 and a gas transfer measurement for DLCO, both expressed as a percentage of predicted and then adjusted for how much lung the planned operation will remove.
2. Exercise testing where the numbers are borderline. A stair climb, a shuttle walk or formal cardiopulmonary exercise testing, because measured performance beats a predicted figure.
3. Cardiac assessment, since the risk factors for coronary disease and for lung cancer overlap almost completely.
4. Smoking cessation, which reduces pulmonary complications and matters more when the operation gets brought forward than when it gets delayed.
5. Prehabilitation where time allows. Two to four weeks of structured exercise before surgery improves measured fitness and is worth arranging when the schedule permits it.

What borderline numbers actually mean

Run the calculation for the operation you are actually being offered

Borderline numbers open a discussion about a smaller resection or about radiation, and they are not automatically a reason to refuse surgery. A predicted postoperative FEV1 that looks marginal for a lobectomy can look comfortable for a segmentectomy, which is one of the practical consequences of the trials above, and the calculation should be done for the specific operation being proposed and never for lobectomy in general.

The operation itself, and the possibility of converting

General anesthetic, a breathing tube that lets the anesthetist deflate the lung being operated on, and a catheter for the bladder. You will be positioned on your side.

The five steps inside the chest

1. Two to four small incisions, usually between one and four centimeters, placed between the ribs without spreading them. A camera goes through one and instruments through the others.
2. The pulmonary artery branch, the vein and the bronchus supplying the lobe or segment are each divided and sealed, most often with a surgical stapler.
3. The specimen comes out through one of the incisions in a bag.
4. The lymph node stations are sampled or cleared and labeled separately.
5. One chest drain is placed through an existing incision, and the lung is reinflated under direct vision before closing.

Two to four hours covers most cases. Longer happens often and signals nothing bad.

Conversion to an open operation

Somewhere between a twentieth and a tenth of planned keyhole lobectomies become open operations, and the reasons are bleeding, dense adhesions, an unexpectedly central tumor, or an anatomical arrangement that cannot be handled safely through the ports. Consent for a keyhole operation is consent for this possibility, and a surgeon who converts when the operation demands it is exercising judgment rather than failing. The wrong incentive here is real, because a surgeon reporting a very low conversion rate is either unusually skilled, unusually selective in which patients they accept, or persisting through situations where they should have opened the chest, and only the first of those three counts as good news. Put the question to them directly. A surgeon comfortable with it will tell you their conversion rate and the reasons behind the last few cases, while a surgeon uncomfortable with it has answered you anyway, just not in words you were meant to hear.

The chest drain, the air leak, and the days in hospital

Most of what happens after a lobectomy comes down to one tube.

One drain removes air and fluid from the space where the lobe used to be, and lets the remaining lung expand to fill it. It comes out once the air leak has stopped and the fluid output has fallen, and everything in the recovery follows from that, including the day you go home. Everything.

Why the walking matters more than the resting

Nothing in that list is improved by lying still. Early walking is the single intervention with the clearest effect on pulmonary complications after lung surgery, and the days spent in a chair instead of a bed are the days that shorten the stay.

Breathing afterwards, and what actually recovers

A lobe accounts for a fifth to a third of one lung, depending which one. Patients expect to feel that loss permanently and most do not, which needs an explanation and not an assertion.

Remaining lung expands into the space while the diaphragm and chest wall adjust, so measured lung function at six to twelve months recovers past what a simple arithmetic subtraction would predict. The Japanese trial put the difference in predicted FEV1 at one year between removing a lobe and removing a segment at 3.5 percentage points, which the investigators had set out in advance as below the threshold they would call clinically meaningful. The American trial put the equivalent gap at six months at two percentage points, favoring the smaller operation in both cases and by a margin that neither set of investigators considered large enough to drive the decision on its own. What that leaves is a pair of trials agreeing that the breathing argument for a smaller resection is real and modest, and that the survival argument, where it exists, runs through something other than lung function alone. That is worth saying plainly, because patients are usually told the opposite.

What that means day to day

Pulmonary rehabilitation after surgery helps, and it is offered far less than it should be. Request a referral before you are discharged, since the programs that exist get volunteered to heart attack patients far more readily than they get volunteered to anyone who has just lost a lobe of lung.

What to be skeptical of

And one that runs the other way

One more that runs the other way. Be wary of anyone treating a lobectomy as a minor procedure because the incisions are small, since the operation inside the chest is identical and the recovery is measured in months.

Having the operation away from home

Lung surgery travels better than most cancer treatment, because it is one admission instead of a course, and it travels badly in one specific way.

How long you need to be here

Reckon on two to three days of assessment before the operation, four to seven days in hospital afterwards for most patients, and a further week to ten days locally before flying. That puts a realistic stay at around two and a half to three weeks. A prolonged air leak is the thing that extends it, so the return flight should be bookable and not booked, and the accommodation should be arranged for longer than the expected stay. The specific way this travels badly is that the pathology report arrives after you have flown home, and the pathology is what decides whether you need chemotherapy, so the arrangement for that conversation has to exist before you leave. Decide who reads the pathology with you and how they reach you, and write it down before the operation rather than after it, because a report that arrives by email with nobody attached to explain it is how an adjuvant chemotherapy decision gets postponed by a month.

Follow-up once you are back home

Once you are back home the handover is what carries you. The operation report naming which lobe or segment was removed and which nodal stations were examined, the full pathology report with the node count and the pathological stage, the discharge x-ray, and a written statement of whether adjuvant treatment is recommended and on what timetable. Anyone following you at home needs all four once you are back home. The adjuvant question is the one that goes wrong when a patient flies home before the pathology is final. Surveillance scanning then runs for years on a schedule that should be written down before you leave.

How a quotation for this operation is built

No prices appear on this page. Nobody can put a figure on an operation before reading the scans and the lung function tests, so what follows sets out the anatomy of a quotation line by line.

Swipe the table sideways on a small screen.

Six lines, and the one to check before any of them

What a quotation leaves out

Establish what happens to the figure if the stay runs long or the operation converts to open, because a quotation built on the uncomplicated course and silent on the alternative has not answered the question that matters. Prolonged air leaks are common. Ask.

VATS lobectomy FAQ

References

• Saji H, Okada M, Tsuboi M, Nakajima R, Suzuki K, Aokage K, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L). A multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial. Lancet. 2022;399(10335):1607-1617.
• Altorki N, Wang X, Kozono D, Watt C, Landrenau R, Wigle D, et al. Lobar or sublobar resection for peripheral stage IA non-small-cell lung cancer. New England Journal of Medicine. 2023;388(6):489-498.
• Lim E, Harris RA, McKeon HE, Batchelor TJP, Dunning J, Shackcloth M, et al. Impact of video-assisted thoracoscopic lobectomy versus open lobectomy for lung cancer on recovery assessed using self-reported physical function. VIOLET RCT. Health Technology Assessment. 2022;26(48):1-162.
• Bendixen M, Jørgensen OD, Kronborg C, Andersen C, Licht PB. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer. A randomised controlled trial. Lancet Oncology. 2016;17(6):836-844.
• Jin R, Zheng Y, Yuan Y, Han D, Cao Y, Zhang Y, et al. Robotic-assisted versus video-assisted thoracoscopic lobectomy. Short-term results of a randomized clinical trial (RVlob trial). Annals of Surgery. 2022;275(2):295-302.